Reports

Cruickshank, M., Cooper, M., Crozier, A., Robertson, C., Aucott, L., Manson, P., Ormerod, A., Scotland, G. and Brazzelli, M. (2022) Deucravacitinib for treating moderate-to-severe plaque psoriasis [ID3859], National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Vadiveloo, T., Scotland, G., Booth, C., Robertson, C., Cruickshank, M., Aucott, L., Kennedy, C., Manson, P., Preston, G. and Brazzelli, M. (2022) Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Revoredo-Giha, C., McNamee, P., Norwood, P. and Akaichi, F. (2022) Economic modelling: reducing health harms of foods high in fat, sugar or salt: final report, Edinburgh: Scottish Government. 

Revoredo-Giha, C., McNamee, P., Norwood, P. and Akaichi, F. (2022) Restricting multi-buy price promotions on high fat, sugar or salt discretionary foods: summary of SRUC analysis on potential calorie and nutrient intake impact, Edinburgh: Scottish Government. 

Boyers, D. (2021) Costing report for a new diagnostic test for the detection of acute compartment syndrome. [Report for Aberdeen Royal Infirmary]. 

Cruickshank, M., Boyers, D., Scott, N., Robertson, C., Manson, P., Lumsden, C., Scotland, G. and Brazzelli, M. (2021) Palforzia for treating peanut allergy. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Cruickshank, M., Imamura, M., Counsell, C., Aucott, L., Manson, P., Booth, C., Scotland, G. and Brazzelli, M. (2021) Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Cruickshank, M., Jacobsen, E., Vadivaloo, T., Imamura, M., Cooper, D., Manson, P., Cooper, K., Boyers, D. and Brazzelli, M. (2021) Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Cruickshank, M., Kennedy, C., Aucott, L., Booth, C., Imamura, M., Vadiveloo, T., Manson, P., Preston, G., Scotland, G. and Brazzelli, M. (2021) Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Imamura, M., Boyers, D., Booth, C., Cooper, D., Cruickshank, M., Manson, P., Urquhart, G. and Brazzelli, M. (2021) Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Imamura, M., Kennedy, C., Aucott, L., Boyers, D., Cruickshank, M., Cooper, D., Manson, P., Omerod, T. and Brazzelli, M. (2021) Secukinumab for treating plaque psoriasis in children and young people. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Kennedy, C., Robertson, C., Cruickshank, M., Ayansina, D., Manson, P., Moroni, F., Brazzelli, M. and Scotland, G. (2021) Teduglutide for treating short bowel syndrome. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Loria-Rebolledo, L.E., Ryan, M., Watson, V., Genie, M.G., Sakowsky, R.A., Powell, D. and Paranjothy, S. (2021) Public acceptability of non-pharmaceutical interventions to control a pandemic in the United Kingdom: a discrete choice experiment, [Preprint] medRxiv 2021.10.12.21264883.

Robertson, C., Booth, C., Ayansina, D., Hernández, R., Manson, P., Herriot, R., Brazzelli, M. and Scotland, G. (2021) Berotralstat for preventing acute attacks of hereditary angioedema. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Aucott, L., Robertson, C., Walker, A., Manson, P., Price, G., Scotland, G. and Brazzelli, M. (2020) Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Bannister, K., Cook, J., Scotland, G., Azuara-Blanco, A., Goulão, B., Heimann, H., Hernández, R., Hogg, R., Kennedy, C., Sivaprasad, S., Ramsay, C. and Chakravarthy, U. (2020) Early detection of neovascular age-related macular degeneration (EDNA): an evaluation of diagnostic accuracy, predictive factors, and cost-effectiveness. Final project report to National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Cruickshank, M., Imamura, M., Booth, C., Aucott, L., Counsell, C., Manson, P., Scotland, G. and Brazzelli, M. (2020) Pre-hospital treatment of status epilepticus in adults: a synthesis of current evidence. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Kopasker, D., Robertson, C., Aucott, L., Vadiveloo, T., Imamura, M., Manson, P., Walker, A., Urquhart, G., Brazzelli, M. and Scotland, G. (2020) Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Scotland, G., Kennedy, C., Imamura, M., Cooper, D., Robertson, C., Booth, C., Vadiveloo, T., Manson, P., Urquhart, G. and Brazzelli, M. (2020) Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer. National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance, Aberdeen Health Technology Assessment Group.

Dasgupta, R., Cameron, S., Aucott, L., MacLennan, G., Kilonzo, M., Lam, T., Thomas, R., Norrie, J., McDonald, A., Anson, K., N'Dow, J., Burgess, N., Clark, C., Keeley, F., MacLennan, S., Starr, K. and McClinton, S. (2019) A multicentre randomised controlled trial of shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic treatment, for ureteric stones (TISU trial). Final project report to National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project Number 10/137/01).

Hagen, S., Bugge, C., Dean, S.G., Elders, A., Hay-Smith, J., Kilonzo, M., McClurg, D., Abdel-Fattah, M., Agur, W.I., Andreis, F., Booth, J., Dimitrova, M., Gillespie, N., Glazener, C., Grant, A., Guerrero, K., Henderson, L., Kovandzic, M., McDonald, A., Norrie, J., Sergenson, N., Stratton, S., Taylor, A. and Williams, L.R. (2019) Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT. Final project report to National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project Number 11/71/03).

Hernández, R., Robertson, C., Scott, N., Scotland, G., Booth, C., Manson, P., Broadhurst, P. and Brazelli, M. (2019) TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices, (NICE Technology Appraisal Guidance - GID-TA10370), Aberdeen Health Technology Assessment Group.

Imamura, M., Cooper, D., Hernández, R., Ormerod, T., Scotland, G. and Brazzelli, M. (2019) Risankizumab for treating moderate-to-severe plaque psoriasis. A fast track appraisal, (NICE Technology Appraisal Guidance - TA596), Aberdeen Health Technology Assessment Group.

Kopasker, D. and Montagna, C. (2019) Insecure employment and mental health: one pathway in the productivity puzzle, Small Project Report, Sheffield PIN - Productivity Insights Network, University of Sheffield.

Robertson, C., Fielding, S., Walker, A., Kopasker, D., Vadiveloo, T., Manson, P., Price, G., Brazelli, M. and Scotland, G. (2019) Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer, (NICE Technology Appraisal Guidance - GID-TA10317), Aberdeen Health Technology Assessment Group.

Ryan, M., McKenzie, L., Mennie, L. and Miedzybrodzka, Z. (2019) Valuing whole genome sequencing to improve diagnosis of rare disorders: a health economic perspective. Report to Scottish Genomics Partnership.

Scottish Science Advisory Council (Ryan, M. was a member of the Writing Group) (2019) Informing the future of genomic medicine in Scotland, Edinburgh: SSAC.

Avenell, A., Robertson, C., Ske, Z., Jacobsen, E., Boyers, D., Cooper, D., Aceves-Martins, M., Retat, L., Fraser, C., Aveyard, P., Stewart, F., MacLennan, G., Webber, L., Corbould, E., Xu, B., Jaccard, A., Boyle, B., Duncan, E., Shimonovich, M. and de Bruin, M. (2018) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis (REBALANCE). Systematic reviews and economic evaluations. Final report submitted to NIHR Health Technology Assessment Programme (Project number: 15/09/04).

Bhattacharya, S., Scotland, G., McCormack, K., Scott, N., Hawthorn, R., Hawe, J., Phillips, K., Norrie, J., Cooper, K. and Clark, J. (2018) A multicentre randomised controlled trial comparing laparoscopic supra-cervical hysterectomy with second generation endometrial ablation for the treatment of heavy menstrual bleeding (HEALTH). Final project report to National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project Number 12/35/23).

Boyers, D., Fielding, S., Cruickshank, M., Imamura, M., Fraser, C., Tighe, J. and Scotland, G. (2018) Inotersen for treating hereditary transthyretin-related amyloidosis, (NICE Highly Specialised Technologies programme), Aberdeen Health Technology Assessment Group.

Denison, F.C., McPherson, G., Scotland, G., Brook-Smith, S., Clarkson, C., Peace, M., Brewin, J., Norman, J.E., Norrie, J. and Lawton, J. (2018) A pragmatic adaptive sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (Got-it trial). Final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project Number 12/29/01).

Hemming, C., Constable, L., Goulao, B., Kilonzo, M., Boyers, D., Elders, A., Cooper, K., Smith, A., Freeman, R., Breeman, S., McDonald, A., Hagen, S., Montgomery, I., Norrie, J. and Glazener, C. (2018) Vault or Uterine prolapse surgery Evaluation: two parallel randomised controlled trials of surgical options for apical compartment pelvic organ prolapse (VUE). Final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Hernández, R., Cruickshank, M., Dimitrova, M., Cooper, D., Aucott, L., Fraser, C., Shimonovich, M., Ormerod, A., Scotland, G. and Brazzelli, M. (2018) Dupilumab for treating adults with moderate to severe atopic dermatitis, (NICE Technology Appraisal Guidance - TA534), Aberdeen HTA Group.

McNamee, P. (2018) Action Learning Set – mapping current expenditure and activity in prescribing in NHS Lanarkshire. Report for Health Economics Network for Scotland and NHS Lanarkshire.

Pol, M. van der (2018) 'Time and risk preferences in older persons in Scotland', in Douglas, E., Wilson, T. and Bell, D. (2018) Healthy ageing in Scotland: the pilot survey (HAGIS), Stirling: Stirling Management School, University of Stirling.

Riley, P., Glenny, A.M., Worthington, H., Jacobsen, E., Robertson, C., Durham, J., Davies, S., Petersen, H. and Boyers, D. (2018) Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation. Final report submitted to NIHR Health Technology Assessment Programme (Project number: 16/146).

Robertson, C., Chong, H., Scotland, G., Cooper, D., Ramsay, C., Urquhart, G. and Aucott, L. (2018) Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer, (NICE Technology Appraisal Guidance - TA580), Aberdeen Health Technology Assessment Group.

Robertson, C., Walker, A., Jacobsen, E., Aucott, L., Herriot, R., Scotland, G. and Brazelli, M. (2018) Lanadelumab for preventing recurrent attacks of hereditary angioedema, (NICE Technology Appraisal Guidance - TA606), Aberdeen Health Technology Assessment Group.

Scotland, G., Dimitrova, M., Ayansina, D., Cruickshank, M., Imamura, M., Fraser, C., Lam, T. and Brazelli, M. (2018) Padeliporfin for treating localised prostate cancer, (NICE Technology Appraisal Guidance - TA546), Aberdeen Health Technology Assessment Group.

Boyers, D., Cruickshank, M., Jacobsen, E., Cooper, C., Fraser, C., Culligan, D. and Scotland, G. (2017) Brentuximab vedotin for relapsed or refractory systemic anaplastic large cell lymphoma, (NICE Technology Appraisal Guidance - TA478), Aberdeen Health Technology Assessment Group.

McNamee, P., Neilson, A.R., Norwood, P., Avenell, A. and Ludbrook, A. (2017) A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight, obesity and diet-related illness, Aberdeen: Food Standards Scotland. [pdf]

Ramsay, C., Clarkson, J., Duncan, A., Lamont, T., Heasman, P., Boyers, D., Goulao, B., Bonetti, D., Bruce, R., Gouick, J., Heasman, L., Lovelock, L., MacPherson, L., McCracken, G., McDonald, A., Mitchell, F., Norrie, J., Pol, M. van der, Sharp, A., Steele, J., Watt, G., Worthington, H. and Young, L. (2017) Improving the Quality of Dentistry (IQuaD): a cluster factorial randomized controlled trial comparing the effectiveness and cost benefit of oral hygiene advice and/or periodontal instrumentation to routine care for the prevention and management of periodontal disease in dentate adults attending dental primary care. Final project report to NIHR (Project Number 09/01/45).

Scotland, G. and Brazzelli, M. (2017) Eluxadoline for treating irritable bowel syndrome with diarrhoea. Evidence Review Group critique of the new economic evidence submitted by the company in response to the Appraisal Consultation Document, (NICE Technology Appraisal Guidance -TA471), Aberdeen Health Technology Assessment Group.

Scotland, G. and Kopasker, D. (2017) Teduglutide for treating short bowel syndrome. Evidence Review Group critique of the new economic evidence submitted by the company in response to the Appraisal Consultation Document, (NICE Technology Appraisal -10048), Aberdeen Health Technology Assessment Group.

Scotland, G., Kopasker, D., Scott, N., Cruickshank, M., Hernández, R., Fraser, C., McLean, M., McKinlay, A. and Brazzelli, M. (2017) Teduglutide for treating short bowel syndrome, (NICE Technology Appraisal -10048), Aberdeen Health Technology Assessment Group.

Skåtun, D., Elliott, R.F., Ejebu, O., McConnachie, A., Rice, N. and Weatherall, K. (2017) The staff market forces factor component of the resource allocation weighted capitation formula: new estimates 2013-2015, Aberdeen: HERU.

Skåtun, D., Leckcivilize, A. and Skåtun, J.D. (2017) The effects of pay restraint on NHS Scotland staff groups within the Agenda for Change pay system. Final Report to the Scottish Terms and Conditions Committee (STAC).

Cruickshank, M., Campbell, C., Choi, Y., Cubie, H., Cuschieri, K., Donaghy, M., Robertson, C., Smart, L., Sullivan, F. and Weller, D. (Neilson, A.R. is on the project team and contributed to Appendix 3 (2016) The Scottish Cervical Cancer Prevention Programme: assessing and modelling the impact of HPV 16/18 immunisation on the performance of current cervical screening performance and the effectiveness of alternative cervical screening strategies to optimise cancer prevention in the HPV immunisation era. Final report submitted to the Chief Scientist Office (CZG/4/528).

Scotland, G., Hernández, R., Robertson, C., Scott, N. and Fraser, C. (2016) Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (men who have not received docetaxel and for whom docetaxel is contraindicated or not suitable): ERG critique of the company submission for re-consideration of current CDF technologies under the new proposed CDF criteria. Report from Aberdeen Health Technology Assessment Group to NICE Appraisal Committee.

Tassie, E., Scotland, G. and Neilson, A.R. (2016) A model based cost-effectiveness analysis of opportunistic screening for identifying atrial fibrillation with a single lead handheld electrocardiogram monitor in general practices in Scotland, Final report. HERU, University of Aberdeen. [pdf]

Watson, A. J., Cook, J., Hudson, J., Kilonzo, M., Wood, J., Bruhn, H., Brown, S., Buckley, B., Curran, F., Jayne, D., Loudon, M., Rajagopal, R., McDonald, A. and Norrie, J. (2016) A pragmatic, multicentre, randomised controlled trial comparing stapled haemorrhoidopexy to traditional excisional surgery for haemorrhoidal disease: the eTHoS Study. Final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Douglas, F., Ejebu, O., Garcia, A., MacKenzie, F., Whybrow, S., McKenzie, L., Ludbrook, A. and Dowler, E. (2015) The nature and extent of food poverty, NHS Health Scotland. [pdf]

Glazener, C., Breeman, S., Elders, A., Hemming, C., Cooper, K., Freeman, F., Smith, A., Hagen, S., Montgomery, I., Kilonzo, M., Boyers, D., McDonald, A., McPherson, G., MacLennan, G. and Norrie, J. (2015) Clinical and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study: results from the PROSPECT Study. Final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Ludbrook, A., Campbell, J., Douglas, F., Michels, K., Müller, I., Furlong, B., De Craemer, M., Vuillemin, A. and Woods, C. (2015) Report on policy monitoring and evaluation based on literature search and rapid review., 3.2.1. DEDIPAC Consortium.

Ludbrook, A. (2015) 'Special focus III: how does minimum unit pricing for alcohol affect different types of drinkers?', in Sassi, F. (ed.) Tackling harmful alcohol use: economics and public health policy, Paris, France: OECD Publishing. [pdf]

Pol, M. van der, Olajide, D., Dusheiko, M., Guthrie, B., Elliott, R.F., Jorm, L.R. and Leyland, A.H. (2015) Avoidable Scottish Hospitalisations (ASH). Final report submitted to Chief Scientist Office.

Scotland, G., Neilson, A. R., Javanbakht, M., Fielding, S., Cruickshank, M., Sharma, P., Fraser, C., Simpson, W. and Brazzelli, M. (2015) Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Report from Aberdeen Health Technology Assessment Group to NICE Single Technology Appraisal Programme.

Scotland, G., Javanbakht, M., Scott, N., Cruickshank, M., Sharma, P., Fraser, C., Simpson, W. and Brazzelli, M. (2015) Ezetimibe for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia. Report from Aberdeen Health Technology Assessment Group to NICE Appraisal Committee.

Azuara-Blanco, A., Banister, K., Boachie, C., McMeekin, P., Gray, J., Burr, J., Bourne, R., Garway-Heath, D., Batterbury, M., Hernández, R., McPherson, G., Ramsay, C. and Cook, J. (2014) Comparative study of automated imaging technologies for the diagnosis of glaucoma (GATE study). Diagnostic accuracy, performance as triage tests, and cost-effectiveness. Final report submitted to the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC).

Eberth, B., Ludbrook, A., Gerdtham, U.-G. and Hernández, R. (2014) Socioeconomic inequalities in health and behaviour: Application of novel approaches to identify health inequality in Scotland and England to inform policy: final report, Edinburgh: Chief Scientist Office.

Hoskins, G., Williams, B., Duncan, E., Sheikh, A., Pinnock, H., Donnan, P. T. and Pol, M. van der (2014) Can eliciting and addressing health-related goals improve asthma control and asthma-related quality of life? Feasibility Phase II pilot randomised controlled trial. Final report submitted to Chief Scientist Office.

Kenter, J. O., Reed, M. S., Irvine, K. N., O'Brien, L., Brady, E., Bryce, R., Christie, M., Church, A., Cooper, N., Davies, A., Evely, A., Everard, M., Fazey, I., Hockley, N., Jobstvogt, N., Molloy, C., Orchard-Webb, J., Ravenscroft, N., Ryan, M. and Watson, V. (2014) UK National Ecosystem Assessment follow-on. Work package report 6: shared, plural and cultural values of ecosystems, Cambridge: UK National Ecosystem Assessment. [link]

Mowatt, G., Hernández, R., Castillo, M., Lois, N., Fraser, C., Aremu, O., Amoaku, W., Burr, J. M., Lotery, A., Ramsay, C. and Azuara-Blanco, A. (2014) Optical coherence tomography for the diagnosis, monitoring, and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.

Pickard, R., Starr, K., MacLennan, G., Kilonzo, M., Lam, T., Thomas, R., Burr, J., McClinton, S. and the SUSPEND Trial Group (2014) Group use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled trial of a calcium channel blocker (nifedipine) and an α-blocker (tamsulosin). The SUSPEND Trial final report submitted to the National Institute for Health Research (NIHR) Health Technology Assessment Programme.